EPO utilization pattern in chronic renal insufficiency patients presenting with anemia: Evolution between 1992 and 1998;Evolution des pratiques médicales dans la prise en charge de l'anémie et la prescription d'érythropoïétine chez les insuffisants rénaux chroniques hémodialysés au cours des six dernières années

Nephrologie

Volumn 23, Issue 3, 2002, Pages 123-130

  Canaud, Bernard ^a   Richard, A ^a   Fagnani, F ^a   Moreau Defarges, T ^a   Guillon, P ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

Anemia; End stage renal disease; EPO; Hemodialysis

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; FEMALE; FRANCE; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE;

ANEMIA; ERYTHROPOIETIN; FRANCE; HUMANS; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; RENAL DIALYSIS;

EID: 0036101628     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial
2. Treatment of anaemia in haemodialysis patients with recombinant erythropoietin
3. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: Safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dépendent patients
4. Erythropoïétine humaine recombinante: 18 Mois d'utilisation continue en hémodialyse de suppléance
5. Recombinant human erythropoietin and the quality of life of endstage renal disease patients: A comparative analysis
6. Improved sexual function in hemodialysis patients on recombinant erythropoietin: A possible role for prolactin
7. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients
8. Epoetin and cognitive function
9. Quality of life and hematocrit level
10. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients
11. The use of recombinant human erythropoietin in predialysis patients
12. Subcutaneous erythropoietin administration in predialysis patients: A single centre prospective study
13. Anemia during the predialysis period: A key to cardiac damage in renal failure
14. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure
15. The impact of recombinant human erythropoietin therapy on renal transplantation
16. Recombinant human erythropoietin treatment of anemia in renal transplant patients
17. Erythropoietin and renal transplantation
18. Benefits and concerns of treating predialysis and renal transplant patients with recombinant human erythropoietin
19. L'érythropoïétine recombinante humaine chez les urémiques en traitement de suppléance
20. Recombinant human erythropoietin: 18-Months' expeérience in hemodialysis patients
21. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative
22. European best practice guidelines for the management of anaemia in patients with chronic renal failure
23. Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin
24. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease
25. Epoetin: A pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life
26. Evidence-based recommendations for the clinical use of recombinant human erythropoietin
27. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients
28. A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease
29. Anemia in hemodialysis patients: Variables affecting this outcome predictor
30. Trends in erythropoietin therapy in the US dialysis population: 1995 to 1998
31. Secular trends in recombinant erythropoietin therapy among the US hemodialysis population: 1990-1996
32. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states
33. Erythropoietin in chronic renal failure
34. Early dosing practices and effectiveness of recombinant human erythropoietin
35. Starting r-HuEPO in chronic renal failure: When, why, and how?
36. Cost of treating predialysis patients with recombinant human erythropoietin
37. In search of an optimal hematocrit level in dialysis patients: Rehabilitation and quality-of-life implications
38. Meeting the challenges of a new millennium: Optimizing the use of recombinant human erythropoietin
39. Optimal hematocrit in patients on dialysis therapy
40. Normalizing hematocrit in dialysis patients improves brain function
41. Complete correction of renal anemia by recombinant human erythropoietin
42. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration
43. Optimizing epoetin therapy in end-stage renal disease: The case for subcutaneous administration
44. Weekly subcutaneous erythropoietin maintains hematocrit in chronic hemodialysis patients
45. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients
46. Optimal route of administration of erythropoietin in chronic renal failure patients: Intravenous versus subcutaneous
47. Two years experience of daily self-administered subcutaneous erythropoietin
48. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients
49. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin
50. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients
51. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations
52. Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis
53. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients
54. Safety of intravenous injection of iron saccharate in haemodialysis patients
55. Strategies for iron supplementation: Oral versus intravenous
56. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients
57. Pathophysiology of renal anemia
58. Predictors of erythropoietin responsiveness in chronic hemodialysis patients
59. Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin
60. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease
61. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients
62. Parathyroidectomy and response to erythropoietin therapy in anaemic patients with chronic renal failure
63. Parathyroidectomy in chronic renal failure: Short- and long-term results on parathyroid function, blood pressure and anemia
64. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients
65. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients
66. Why hemodialysis patients are in a prooxidant state? What could be done to correct the pro-antioxidant imbalance